Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease

Journal of Neural Transmission

Volumn 120, Issue 5, 2013, Pages 761-765

  Müller, Thomas ^a   Hoffmann, Josef A ^b   Dimpfel, Walter ^c   Oehlwein, Christian ^d  

^a St Joseph's Hospital   (Germany)

^b TEVA Pharma GmbH   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d NONE

Author keywords

Parkinson's disease; Rasagiline; Selegiline

Indexed keywords

AMANTADINE; AMPHETAMINE; BUDIPINE; CABERGOLINE; ENTACAPONE; GLUTAMATE RECEPTOR; LEVODOPA; LISURIDE; METHAMPHETAMINE; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; SELEGILINE;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; HUMAN; LOCOMOTION; MALE; MENTAL HEALTH; MINI MENTAL STATE EXAMINATION; MOOD; OPEN STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; SLEEP; SLEEP DISORDER; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; AMPHETAMINE; ANTIPARKINSON AGENTS; DRUG SUBSTITUTION; FEMALE; HUMANS; INDANS; MALE; METHAMPHETAMINE; MIDDLE AGED; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SELEGILINE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84878012140     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0927-3     Document Type: Article

References (34)

1. Antonini G, Morino S, Fiorelli M, Fiorini M, Giubilei F (1997) Selegiline in the treatment of hypersomnolence in myotonic dystrophy: a pilot study. J Neurol Sci 147:167-169
2. Bar-Am O, Weinreb O, Amit T, Youdim MB (2010) The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem 112:1131-1137
3. 2: aufmerksamkeits-belastungs-test. Göttingen, Hogrefe Verlag
4. Brotchie J, Johnston TH, Visanji NP (2011) 1-Aminoindan, a main metabolite of rasagiline, enhances dopamine release and provides symptomatic benefit in an animal model of Parkinson's disease. Parkinsonism Relat Disord 2007:102
5. Buysse DJ, Angst J, Gamma A, Ajdacic V, Eich D, Rossler W (2008) Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 31:473-480
6. Chen JJ, Swope DM, Dashtipour K (2007) Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 29:1825-1849
7. Dimpfel W, Hoffmann J (2011) Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. BMC Pharmacol 11:2
8. Dusek P, Buskova J, Ruzicka E, Majerova V, Srp A, Jech R, Roth J, Sonka K (2010) Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. Clin Neuropharmacol 33:186-190
9. Fernandez HH, Chen JJ (2007) Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol 30:150-168
10. Garcia-Borreguero D, Schwarz C, Larrosa O, de la LY, de Garcia YJ (2003) L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment. Neurol 61:1008-1010
11. Gregory AM, Buysse DJ, Willis TA, Rijsdijk FV, Maughan B, Rowe R, Cartwright S, Barclay NL, Eley TC (2011) Associations between sleep quality and anxiety and depression symptoms in a sample of young adult twins and siblings. J Psychosom Res 71:250-255
12. Hauser RA, Auinger P, Parkinson Study Group (2011) Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord 26:813-818
13. He S, Grasing K (2006) L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; insights towards selegiline's mechanism of action. Pharmacol Biochem Behav 85:675-688
14. Kahn-Greene ET, Killgore DB, Kamimori GH, Balkin TJ, Killgore WD (2007) The effects of sleep deprivation on symptoms of psychopathology in healthy adults. Sleep Med 8:215-221
15. Killgore WD (2010) Effects of sleep deprivation on cognition. Prog Brain Res 185:105-129
16. Kronstrand R, Ahlner J, Dizdar N, Larson G (2003) Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication. J Anal Toxicol 27:135-141
17. Laine K, Anttila M, Huupponen R, Maki-Ikola O, Heinonen E (2000) Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol 23:22-27
18. Lecht S, Haroutiunian S, Hoffman A, Lazarovici P (2007) Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag 3:467-474
19. Mayer G, Ewert MK, Hephata K (1995) Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 18:306-319
20. Nishida K, Itoh S, Inoue N, Kudo K, Ikeda N (2006) High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users. J Anal Toxicol 30:232-237
21. Pollo A, Benedetti F (2009) The placebo response: neurobiological and clinical issues of neurological relevance. Prog Brain Res 175:283-294
22. Przuntek H, Bittkau S, Bliesath H, Buttner U, Fuchs G, Glass J, Haller H, Klockgether T, Kraus P, Lachenmayer L, Müller D, Müller T, Rathay B, Sgonina J, Steinijans V, Teshmar E, Ulm G, Volc D (2002) Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol 59:803-806
23. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947-954
24. Reinish LW, MacFarlane JG, Sandor P, Shapiro CM (1995) REM changes in narcolepsy with selegiline. Sleep 18:362-367
25. Roca J, Fuentes LJ, Marotta A, Lopez-Ramon MF, Castro C, Lupianez J, Martella D (2012) The effects of sleep deprivation on the attentional functions and vigilance. Acta Psychol (Amst) 140:164-176
26. Roselaar SE, Langdon N, Lock CB, Jenner P, Parkes JD (1987) Selegiline in narcolepsy. Sleep 10:491-495
27. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51:604-612
28. Siu EC, Tyndale RF (2008) Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther 324:992-999
29. Taylor DJ (2008) Insomnia and depression. Sleep 31:447-448
30. Taylor DJ, Lichstein KL, Durrence HH (2003) Insomnia as a health risk factor. Behav Sleep Med 1:227-247
31. Thorpy M (2007) Therapeutic advances in narcolepsy. Sleep Med 8:427-440
32. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR (2010) Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26:90-99
33. Verhagen ML, Del DP, van den MP, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurol 50:1323-1326
34. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM (2004) Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3 month, randomized, placebo-controlled study. Mov Disord 19:426-432